Oncotherapy science (OTS) is“ to deliver cancer therapeutics and treatments with higher efficacy and fewer side effects to patients suffering from cancer as soon as possible, and to overcome the fight against cancer. Was established with the aim of OTS brought Professor Genomix (Science that handles genetic information systematically) as a pioneer in the medical field with Prof. Atsushi Nakamura (Director, Cancer Precision Medical Research Center, Institute of Cancer, Professor Emeritus, The University of Tokyo, Professor Emeritus of Chicago University) Joint research to identify target molecules suitable for cancer drug development based on comprehensive gene expression analysis, and promote research and development of small molecule drugs, cancer peptide vaccines and antibody drugs for those targets.

Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

Eli Lilly engages in the discovery, development, manufacture, and sale of products in the pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.

Xiamen Innovax Biotech Co., Ltd. manufactures vaccines and diagnostic reagents. It focuses on research and development, manufacturing, marketing of vaccine, diagnosis kit and medical equipment. The company was founded in 2005 and is headquartered in Xiamen, China.

PreTect AS engages in the development of sophisticated biomedical diagnostic kits based on the detection of RNA and proteins. Its products include PreTect SEE, PreTect HPV-Proofer HV, PreTect X, and PreTect TM. The company was founded in 1998 and is headquartered in Klokkerstua, Norway.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Exelixis is focused on discovering, developing and commercializing therapies for the treatment of cancer and other serious diseases. The majority of its programs focus on the discovery and development of small molecule drugs for cancer. The Company has a pipeline of compounds in various stages of development for the treatment of cancer and various metabolic, cardiovascular and inflammatory disorders. All of its development compounds were generated through its internal drug discovery activities, although it is developing certain of these compounds in collaboration with partners and has out-licensed to others. The Company is focusing its development activities on its clinical compounds, XL184, XL147 and XL765. XL184, the Company's advanced drug candidate, inhibits MET, VEGFR2 and RET, proteins that are key drivers of tumor growth and/or vascularization. XL147 is a selective inhibitor of PI3K while XL765 is a dual inhibitor of PI3K and mTOR.

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

Abbisko Therapeutics Co., Ltd. engages in the research and development of biomedicine and biotechnology. Its business includes technology transfer, technical advisory, and technical services. The company was founded on April 12, 2016 and is headquartered in Shanghai, China.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Gen-Probe Incorporated develops, manufactures, and markets nucleic acid probe-based products used for the clinical diagnosis of human diseases, and for screening donated human blood in North America and internationally. The company markets and sells its clinical diagnostic products in the United States directly and outside the United States primarily through distributors, as well as through its direct sales force, and the company also markets and sells its other products through collaborative partners. The company's blood screening products are marketed and distributed worldwide by Novartis. In addition, the company has agreements with Siemens (as assignee of Bayer Corporation), bioMérieux, Inc., or bioMérieux, and Fujirebio, Inc., through its subsidiary Rebio Gen, Inc., or Rebio Gen, to market products in various overseas markets. The company is developing NAT assays and instruments for the detection of harmful pathogens in the environment and biopharmaceutical and beverage manufacturing processes. The company has entered into collaboration agreements with GE Infrastructure Water and Process Technologies, or GEI, a unit of General Electric Company, and Millipore Corporation, or Millipore, under which the company would be primarily responsible for developing and manufacturing assays for exclusive use or sale by its collaborative partners in specified fields with in the industrial testing market. Products The company has applied its core technologies to develop multiple product lines, all of which utilize its expertise in NAT probes, sample collection and processing. The company categorizes its products into clinical diagnostic products and blood screening products. Clinical Diagnostic Products Within its clinical diagnostic product group, the company has developed products for the detection of non-viral and viral microorganisms and for the detection of markers for cancer. Clinical Diagnostic Products for the Detection of Non-Viral Microorganisms The company has developed FDA-approved amplified and non-amplified NAT assays that detect non-viral micro-organisms primarily for use in clinical diagnostics. The company's principal products for the detection of non-viral microorganisms include its non-amplified AccuProbe and PACE family of products and its amplified Mycobacterium Tuberculosis Direct Test and amplified APTIMA products. AccuProbe Products: The company's AccuProbe Culture Identification products are tools for the identification of mycobacterial, fungal and bacterial pathogens, with sensitivities and specificities approaching 100% in most cases. These products allow for the detection of target organisms from primary cultures, eliminating the additional labor of purifying secondary cultures. All AccuProbe Culture Identification assays are based on its HPA technology. As part of its AccuProbe Culture Identification product line, the company also has developed a procedure to detect GBS from broth culture. Group A Streptococcus Direct: The Group A Streptococcus Direct Test, or GASDirect assay, is a NAT assay for the direct detection of Streptococcus pyogenes in one hour from a throat swab. PACE Product Family: The company's PACE 2C offers the testing for both chlamydia infections and gonorrhea from a single patient specimen.

Oncolix, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of medical therapies for the treatment of various cancers including ovarian, breast, uterine, and prostate. Its brand Prolanta is a drug designed to block the effect of human prolactin in cancers, either as a stand-alone therapy or in combination with other drugs, by blocking the effect of human prolactin. The company was founded on June 2013 and is headquartered in Houston, TX.

OBI Pharma, Inc. engages in the development and licensing of novel therapeutic agents for unmet medical needs against cancer. Its products include Adagloxad Simolenin, which is a late-stage novel active immune-oncology Globo Series-based therapeutic vaccine for the treatment of epithelial cancers, such as breast, ovarian, lung, prostate, colon, gastric, and pancreatic cancer. The company was founded by Michael N. Chang on April 29, 2002 and is headquartered in Taipei, Taiwan.

Attobio Pharmaceutical (Suzhou) Co. Ltd. engages in the development of biomedical technology and products. Its business activities include the innovation of products designed to improve the level of preventive medicine and early detection of disease to provide accurate diagnostic techniques, and the import and export of biological reagents and biotechnology. The company was founded by Xiao Jia Chang on May 7, 2012 and is headquartered in Suzhou, China.

ZymoGenetics is focused on the discovery, development, and early manufacture of therapeutic proteins. ZymoGenetics is a fully-integrated research and development organization with a broad range of skills and technologies, including scientific computing, molecular and cellular biology, protein chemistry, antibody generation and engineering, clinical development and operations, regulatory affairs, quality, drug formulation, process development and protein manufacturing.

Under the corporate philosophy of "Value Creation with Respect for Man's Life and Dignity", IL-YANG PHARM was established in 1946 and stepped forward with the growth of Korean pharmaceutical industry. Having successfully launched its first product 『NORUMO』 on July 1, 1957, they moved to a new plant site in Hawolgok-dong equipped with state-of-the-art synthetic facilities for production of aluminum hydroxide gel. Entering the 1960's, they quickly expanded under management modernization with new product development and sought multilateral changeover in management in the 19R70's. Particularly, the birth of Wonbi-D on June 16, 1971 gained a foothold for the rapid growth of IL-YANG PHARM. After founding Neusiline composition plant in Yongin in November 1972, they went through business opening in 1742 and became the 125th listed company in Korea.

Epidauros Biotechnologie AG, part of AbbVie, Inc., is a German company located in Bernried. The firm specializes in pharmacogenomics research. Clinical Data BV acquired Epidauros Biotechnologie AG from Deutsche Effecten & Wechsel Beteiligungs AG on August 23, 2007 for $11.83 million.

Far East Super Laboratories Ltd. is a private company headquartered in China that operates testing laboratories.

Arbor Vita Corp. engages in discovery and developing of drugs. It targets cellular regulators, PDZ proteins, to accelerate the discovery and development of human therapeutics, and diagnostics. The company was founded by Peter S. Lu in 1998 and is headquartered in Fremont, CA.

IncellDx, Inc. detects and monitors life threatening diseases. It offers transformative diagnostic and prognostic clinical patient information based on an innovative technology platform that enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers. The company was founded by Bruce K. Patterson and Carol Penfold-Patterson on December 3, 2009 and is headquartered in Menlo Park, CA.